Neuberger Berman Group
RGNX icon

Neuberger Berman Group’s Regenxbio RGNX Stock Holding History

Neuberger Berman Group’s Portfolio RGNX Stock Details RGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-19,839
Closed -$1.02M – 1589
2019
Q2 		$1.02M Buy
19,839
+7,714
+64% +$385K ﹤0.01% 1162
2019
Q1 		$695K Buy
+12,125
New +$601K ﹤0.01% 1196

Other funds holding RGNX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $7.71B AUM 4.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
WM
WS Management Jacksonville, Florida $1.14B AUM 139.27% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Neuberger Berman Group's RGNX Position: Q3 2019 in Review

Neuberger Berman Group sold out of Regenxbio (RGNX) in Q3 2019, closing a stake of 19,839 shares — an estimated $1.02M sold.

Neuberger Berman Group first reported a position in RGNX in Q1 2019 and held it in 2 quarters. The position peaked at $1.02M in Q2 2019. 168 funds tracked by Wall St. Rank hold RGNX as of Q3 2019.

  • Neuberger Berman Group reported no remaining Regenxbio position as of Q3 2019 after selling out during the quarter.
  • Neuberger Berman Group sold 19,839 Regenxbio shares in Q3 2019, an estimated $1.02M.
  • Neuberger Berman Group first reported a position in Regenxbio in Q1 2019 and held it in 2 quarters.
  • Neuberger Berman Group's Regenxbio position peaked at $1.02M in Q2 2019.
  • 168 funds tracked by Wall St. Rank held Regenxbio as of Q3 2019.

Based on Neuberger Berman Group's 13F filing for Q3 2019, filed 13 Nov 2019.